Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27308415 | 0.91 | MAPT (0.43) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL25838976 | 0.91 | MAPT (0.43) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL3198146 | 0.90 | KDM4E (0.47) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL3207481 | 0.90 | MAPT (0.47) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL2430255 | 0.90 | KDM4E (0.50) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL8980551 | 0.86 | CA12 (0.57) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL829753 | 0.86 | CA12 (0.54) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL681252 | 0.84 | KDM4E (0.63) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL14590043 | 0.84 | GAA (0.47) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL19993672 | 0.84 | MAPT (0.42) | MAPTCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4429663-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023086799-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086799-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | H. LUNDBECK A/S (DK) | 2017-08-24 | — | — | US | disclosed |
| US-9682967-B2 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. LUNDBECK A/S (DK) | 2017-06-20 | — | — | US | disclosed |
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | H. LUNDBECK A/S (DK) | 2015-12-24 | — | — | US | disclosed |
| EP-2135671-B1 | Catalyst and method for producing carboxylic acid and/or carboxylic anhydride in the presence of the catalyst | MITSUBISHI GAS CHEMICAL CO (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-8809451-B2 | Fluorinated dicarboxylic acid derivative and polymer obtained therefrom | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809451-B2 | Fluorinated dicarboxylic acid derivative and polymer obtained therefrom | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-05 | — | — | US | disclosed |
| US-20110301305-A1 | Fluorinated Dicarboxylic Acid Derivative and Polymer Obtained Therefrom | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301305-A1 | Fluorinated Dicarboxylic Acid Derivative and Polymer Obtained Therefrom | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| EP-2392555-A2 | FULLERENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME | Korea Research Institute of Chemical Technology (KRICT) (KR) | 2011-12-07 | — | — | EP | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| WO-2010095678-A1 | FLUORINATED DICARBOXYLIC ACID DERIVATIVE AND POLYMER OBTAINED THEREFROM | セントラル硝子株式会社 (JP) | 2010-08-26 | — | — | WO | disclosed |
| US-20100036138-A1 | CATALYST AND METHOD FOR PRODUCING CARBOXYLIC ACID AND/OR CARBOXYLIC ANHYDRIDE IN THE PRESENCE OF THE CATALYST | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-2135671-A2 | Catalyst and method for producing carboxylic acid and/or carboxylic anhydride in the presence of the catalyst | Mitsubishi Gas Chemical Company, Inc. (JP) | 2009-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368231-A1 | N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS | SORT1, NRP1, SELPLG | MAPT 22/4885CA12 4352/4885CA1 4002/4885 |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | F2R, F2RL1, F2RL3 | MAPT 3412/4885CA12 4697/4885CA1 4509/4885 |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | SCO2, VDAC2, TRPA1 | MAPT 661/4885CA12 3029/4885CA1 3134/4885 |
| US-20110301305-A1 | Fluorinated Dicarboxylic Acid Derivative and Polymer Obtained Therefrom | MCCC2, AFF2, F13A1 | MAPT 3852/4885CA12 11/4885CA1 5/4885 |
| US-20170239226-A1 | N-Substituted-5-Substituted Phthalamic Acids as Sortilin Inhibitors | SORT1, NRP1, SELPLG | MAPT 27/4885CA12 4323/4885CA1 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.